Cytek Biosciences, Inc. · NASDAQ:CTKB
Cytek Biosciences — Investor Presentation (November 2023)
18 slides from Cytek Biosciences's investor presentation, Nov 28, 2023
Slide 1: Corporate Presentation November 2023
Corporate Presentation November 2023 Dr. Wenbin Jiang, CEO Patrik Jeanmonod, CFO Paul Goodson, Investor Relations Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek’s business and operational goals and strategies; Cytek’s business development plans; Cytek’s est
Slide 3: Cytek's Leadership Team
Cytek’s Leadership Team Wenbin Jiang, Ph.D. Chief Executive Officer Valerie Barnett General Counsel Allen Poirson, Ph.D. SVP, Corporate and Business Development Ming Yan, Ph.D. Chief Technology Officer Patrik Jeanmonod Chief Financial Officer Philippe Busque SVP, Global Sales and Services Paul Goods
Slide 4: Investing to Capture the Cell Analysis Opportunity
Investing to Capture the Cell Analysis Opportunity1 2020 Reagents 2018 Northern Lights™ 2017 Cytek Aurora ™ 2021 Cell Sorter Strong Financial Profile Broad Customer Base and Global Presence Validated Technology Platform 1,500+ Customers 1,997 Cytek Units Placed $183.1M $9.3M TTM Revenue/ A-EBITDA 70
Slide 5: Global Scale and Reach with Diversified Revenue Mix
Global Scale and Reach with Diversified Revenue Mix Nine months ended September 30, 2023 % Revenue by Industry Since launch of Aurora Series in 20171… 1,500+ Customers 150+ Biopharma Companies 70+ Countries ~700 Employees WW Applications, Service & Sales % Revenue by Region Fremont (Headquarters) Be
Slide 6: Acquisition of Luminex's Flow Cytometry and Imaging Business provides key strategic benefits
Acquisition of Luminex’s Flow Cytometry and Imaging Business1 provides key strategic benefits (1) Acquisition closed February 28, 2023 Enhances technical capabilities Expands customer base and commercial reach Significant operational synergies across service 1 1,500+ Customers 70+ Countries 7,000+ U
Slide 7: Broad product portfolio to capture the cell analysis opportunity
Broad product portfolio to capture the cell analysis opportunity 2017 Aurora 2018 Northern Lights 2021 Cell Sorter 2020 Reagents 2021 Tonbo 2022 CE-IVDD 2023 Amnis® & Guava® Amnis ImageStream® Amnis FlowSight® Amnis CellStream® Guava easyCyte® Guava® Muse®
Slide 8: Cytek Technology Enables Applications
Cytek Technology Enables Applications FOOTNOTE Total Peer Reviewed Scientific Publication by Application 1,450+ Cytek Peer-Reviewed Publications
Slide 9: Why Customers Choose Cytek
Why Customers Choose Cytek Deeper assessment of patient immune status -- before and after treatment -- for many applications including cancer, COVID, inflammation, drug discovery Fully Standardized across experiments and laboratory sites Isolate rare cells that cannot be seen on other systems for de
Slide 10: We Provide an End-to-End Platform of FSP Solutions
FOOTER Aurora Northern Lights Cell Sorter Automatic sample loader We Provide an End-to-End Platform of FSP Solutions Instruments Services & Application support Reagents and Kits Data Acquisition and Analysis Software
Slide 11: More markers per tube, makes tests more powerful and cost-effective
More markers per tube, makes tests more powerful and cost-effective Clinical Labs 12 Markers per tube “Dirty” Data Research Labs 30 – 40 Markers per tube Conventional Flow Cytometry Cytek Flow Cytometry Full Spectrum Profiling™ Technology 40 Markers per tube Clinical & Research Labs High sensitivity
Slide 12: Cytek's Four Business Pillars
Cytek’s Four Business Pillars FOOTNOTE Instruments Performance Intelligence Ease of use Compact Lowest cost Applications Enabler Panels/kits Flexibility Functionality/Purposes Volume/repeating Bioinformatics Storage Analysis Optimization Management Exchanges Clinical Regulatory LDT Menu AI Standardi
Slide 13: Cytek's Operational and Shareholder Goals
Cytek’s Operational and Shareholder Goals Commitment to Shareholder Value Creation Capital Efficiency Operation Excellence Maximize Free Cash Flow Maintain Positive A-EBITDA on annual basis Execution Speed Smart Acquisitions, Licenses and Joint Ventures FOOTNOTE
Slide 14: Thank You
o°. CYTEK’ a “wl qe” eet cen THe convenrionat Thank You
Slide 15: Appendix
Appendix
Slide 16: Our FSP Technology is Powered by Patented Innovative Designs
Our FSP Technology is Powered by Patented Innovative Designs FOOTNOTE The fluorescence spectrum from each laser source is collected from multiple laser excitation The fluorescence from each laser source is collected by each corresponding detector array module Use of APD detectors maximizes sensitivi
Slide 17: Advancing Cell Analysis with Our Unique FSP Technology
Advancing Cell Analysis with Our Unique FSP Technology FOOTNOTE Conventional Cytek’s FSP™ Technology Our FSP platform was purpose-built to advance the next generation of cell analysis by delivering deep insights, high throughputs and ease of use FSP technology enables high sensitivity and high throu
Slide 18: GAAP to Non-GAAP (GP and EBITDA)
GAAP to Non-GAAP (GP and EBITDA)
Cytek Biosciences — Investor Presentation (November 2023) on 6ix